CoChat

Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors

Suzuki, Kazumi, Miura, Yutaka, Mochida, Yuki, Miyazaki, Takuya, Toh, Kazuko, Anraku, Yasutaka, Melo, Vinicio, Liu, Xueying, Ishii, Takehiko, Nagano, Osamu, Saya, Hideyuki, Cabral, Horacio, Kataoka, Kazunori · 2019 · Journal of Controlled Release
Cited by 95

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Nanomedicine modification with ligands directed to receptors on tumor blood vessels has the potential for selectively enhancing nanomedicine accumulation in malignant tissues by overcoming the vascular barrier of tumors. Nevertheless, the development of broadly applicable ligand approaches capable of promoting the transvascular transport of nanomedicines in a wide spectrum of tumors has been elusive so far. By considering the indispensable and persistent glycolytic fueling of tumors, we developed glucose‐installed polymeric micelles loading cisplatin (Gluc‐CDDP/m) targeting the glucose transporter 1 (GLUT1), which is overexpressed in most tumors and present on vascular endothelial cells, toward improving the delivery efficiency and therapeutic efficacy. The design of the glucose ligands on Gluc‐CDDP/m was engineered to control the conjugation via the carbon 6 of the glucose moieties, as well as the ligand density on the poly (ethylene glycol) (PEG) shell of the micelles. The series of micelles was then studied in vitro and in vivo against GLUT1‐high human squamous cell carcinoma of the head and neck OSC‐19 cells and GLUT1‐low human glioblastoma‐astrocytoma U87MG cells. Our results showed that precisely tuning the micelles to have glucose ligands on 25% of their PEG chains increased the efficacy against the tumors by significantly enhancing the tumor accumulation, even in GLUT1‐low U87MG tumors. The enhancement of the intratumoral levels of these micelles was hindered by concomitant administration of glucose, or the GLUT1 inhibitor STF‐31, confirming a GLUT1/glucose‐mediated increment of the accumulation. Intravital confocal laser scanning microscopy imaging of tumor tissues further demonstrated the rapid extravasation and penetration of Gluc‐CDDP/m in OSC‐19 tumors compared to non‐targeted CDDP/m. These findings indicate GLUT1‐targeting as a promising approach for overcoming the vascular barrier and boosting the delivery of nanomedicine in tumors. Graphical abstract Figure. No Caption available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2019.02.021

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 95

Metadata

Authors
Suzuki, K., Miura, Y., Mochida, Y., Miyazaki, T., Toh, K., Anraku, Y., Melo, V., Liu, X., Ishii, T., Nagano, O., Saya, H., Cabral, H., & Kataoka, K.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2019-05
Volume
301
Pages
28-41
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2918722985
Cited by
95
References
12
FWCI
2.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.